Genetics, Inc. (Nasdaq: SGEN) and Takeda
Pharmaceutical Company Limited (TSE:4502) today announced four-year
overall survival (OS) data from the ADCETRIS (brentuximab vedotin)
pivotal Phase 2 clinical trial in relapsed or refractory systemic
anaplastic large cell lymphoma (ALCL). ADCETRIS is an antibody-drug
conjugate (ADC) directed to CD30, which is expressed in classical
Hodgkin lymphoma (HL) and systemic ALCL, a type of T-cell lymphoma.
for Seattle Genetics and Takeda Announce Four-Year Survival Data from ADCETRIS® (Brentuximab Vedotin) Pivotal Trial in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma at ASH Annual Meeting investment picks